TACROLIMUS EXTENDED

Astellas Pharma Canada, Inc.SITEMAP | WORLDWIDE | FRAN AIS | HOME Advagraf (tacrolimus extended release capsules), marketed by Astellas Pharma Canada, Inc., has been approved by Health Canada for the prevention of organ rejection in patients receiving an allogeneic kidney transplant."Kidney transplantation is a life-altering experience which places a great deal of responsibility on a patient to take multiple medications at different times of the day to avoid compromising the kidney transplant," says Dr. Sita Gourishankar, a nephrologist in the University of Alberta's Department of Nephrology. "A once-daily anti-rejection therapy will be of considerable benefit and will help simplify the drug regimen required by post-transplant patients.